Dry Eye Clinical Trial
Official title:
The Role of Cytokines and Mast Cell in the Pathogenesis of Ocular Surface Inflammation Diseases Including Superior Limbic Keratoconjunctivitis, Conjunctivochalasis, and Dry Eye
The specific aims of the the investigators studies are as follows:
- To collect the tear samples from patients with different ocular surface disorders,
including SLK, conjunctivochalasis, and keratoconjunctivitis sicca (KCS).
- To evaluate the differential expression of tear cytokines and pH values between
different ocular surface disorders.
- To collect the surgical conjunctival specimens from the patients with SLK and
conjunctivochalasis.
- To evaluate the factors inducing mast cell migration and how mast cell is activated in
SLK via surgical specimens and cultivated fibroblast.
1. Detection of various tear cytokine levels in patients with superior limbic
keratoconjunctivitis, conjunctivochalasis, and keratoconjunctivitis sicca
- Basal tear samples will be collected atraumatically from the inferolateral tear
meniscus by using glass capillary tubes. Care is taken to avoid touching the corneal
and conjunctival surface. Approximately 30 μl of tear samples is obtained, and then the
samples are centrifuged for 10 minutes at 1500 rpm (225g). Tear sample are placed in
microtubes (Eppendorf) and stored at -70°C. IL-1β, IL-17, TNF-α, and IFN-γ levels will
be measured by enzyme-linked immunosorbent assay kits.
2. Immunohistochemistry stain method for conjunctival specimens - The conjunctiva will be
collected from SLK and conjunctivochalasis patients who received superior and inferior
bulbar conjunctival resection as needed. The redundant conjunctiva noted after peritomy
during cataract or retinal surgery will be excised to serve as a normal control. The
conjunctival specimens of all the SLK, conjunctivochalasis, and control groups are sent
to the pathology department for routine paraffin embedding and hematoxylin and eosin
staining. The surgical specimens are placed into 4% paraformaldehyde at 4 C for one to
two days and then stored in 1% sodium phosphate buffer at 4 C. They then are embedded
in paraffin. To enhance tissue adhesion, 5-micrometer thick sections are mounted on
glass slides pre- treated with Vectabond (Vector Laboratories, Burlingame, California,
USA). The paraffin sections are deparaffinized, rehydrated and washed with
phosphate-buffered saline (PBS; pH 7.4). Antigen retrieval is performed by immerse the
sections in 0.1% trypsin in water bath for 15 mins. The endogenous peroxidase activity
is quenched by placing the slides in 3% hydrogen peroxide. The slides are then blocked
with serum followed by incubation with primary antibodies. Primary antibodies (TSL and
SCF) are incubated overnight at 4°C. Thereafter, incubation with biotin conjugated
secondary antibody is performed at room temperature for 60 min. Further, incubation
with avidin-biotin horseradish peroxidase complex is then performed at room temperature
as well for 30 min using Vectastain elite® ABC kit (Vector labs, CA USA). The location
where the enzyme is bound will be visualized by the addition of the substrate
3,3'-diaminobenzidine (DAKO, CA, USA), a chromogen which produces a brown insoluble
precipitate. The sections are then counterstained with haematoxylin, which is followed
by dehydration and mounting with Vecta Mount Mounting medium was used to evaluate the
slides.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06159569 -
Performance and Tolerability of the Medical Device LACRIACT
|
N/A | |
Completed |
NCT05027087 -
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
|
Phase 3 | |
Completed |
NCT05102409 -
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
|
Phase 2 | |
Completed |
NCT04081610 -
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
|
Phase 1 | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT03418727 -
Dry Eye Disease Study With Brimonidine
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04527887 -
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
|
Phase 4 | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT04553432 -
Dry Eye OmniLenz Application of Omnigen Research Study
|
Phase 4 | |
Recruiting |
NCT04109170 -
Dry Eye Evaluation System Based on Bioinformatics
|
||
Completed |
NCT04105842 -
Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
|
N/A | |
Completed |
NCT05505292 -
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04668131 -
Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease
|
N/A | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT02235259 -
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
|
Phase 2 | |
Not yet recruiting |
NCT02218827 -
Topical Steroid Treatment For Dry Eye
|
N/A | |
Completed |
NCT01959854 -
Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye
|
N/A |